12-12:20: Dr. Daniel Grosu
Prenatal Screening as a Key Employee Benefit
Summary: Noninvasive prenatal screening (NIPS) is a highly accurate screening method for detecting fetal chromosomal abnormalities from a simple maternal blood draw. This presentation explains the clinical value of NIPS and why it is significantly better for pregnant women than conventional methods. The presentation further highlights the current insurance coverage landscape for NIPS, and why it should be a covered benefit for all employees.
- cfDNA based NIPS is the most accurate screening method for fetal chromosomal abnormalities
- It has the highest detection rate and the lowest false positive rate
- Preferred by both patients and physicians
- Only some commercial insurers cover NIPS for all pregnant women
- Do all your employees have access to NIPS as a covered benefit?
12:20-12:35: Jake Velie, CEO, Rx-Precision
Effective Management In High-Risk Populations Through Appropriate Use of Genomic Data
Summary: With high risk patients, one size does NOT fit all when it comes to prescription medications, especially considering the complexity of these patient cases. There are highly effective genomic tools available to help guide and refine treatment plans, and these important genomic tools are proven to aid in reducing costs. Using genetic information to guide drug and dosage selection and navigate the best treatment options minimizes wasted time and money on ineffective treatments and dramatically improves the patient experience both during and after treatment. Learn how to implement these powerful tools and how to change the trajectory of your high-risk, high-cost outcomes while creating happier employees that are not only at work but more productive.
- Recognize important genomic tools;
- Understand ways medical genomics can aid in mitigating costs and improve lives of patients/employees.
12:35-12:50: Fireside Chat w/Dr. Grosu - C.A.PS., Jake Velie - Rx-Precision, and Erynn Gordon - Genome Medical
Moderated by Joe Connelly, WellVia Genetics